Ainos Inc
NASDAQ:AIMD

Watchlist Manager
Ainos Inc Logo
Ainos Inc
NASDAQ:AIMD
Watchlist
Price: 1.765 USD 0.86% Market Closed
Market Cap: 8.5m USD

Ainos Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Ainos Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Ainos Inc
NASDAQ:AIMD
Cash from Operating Activities
-$4.6m
CAGR 3-Years
-14%
CAGR 5-Years
-54%
CAGR 10-Years
-28%
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$20.9B
CAGR 3-Years
-3%
CAGR 5-Years
5%
CAGR 10-Years
15%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$9.7B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$13.1B
CAGR 3-Years
10%
CAGR 5-Years
4%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
$3.7B
CAGR 3-Years
-3%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$5.1B
CAGR 3-Years
-4%
CAGR 5-Years
18%
CAGR 10-Years
15%
No Stocks Found

Ainos Inc
Glance View

Market Cap
8.5m USD
Industry
Biotechnology

Ainos, Inc. engages in the discovery and development of pharmaceutical and biotech products. The company is headquartered in San Diego, California and currently employs 34 full-time employees. The firm is researching for the treatment of human disease indications, including Sjogren’s syndrome, thrombocytopenia, and other indications using interferon-alpha. The firm is also developing and manufacturing point-of-care testing rapid test kit products that include diagnostics for COVID-19, pneumonia, vaginal infection and helicobacter pylori bacterial infection. Its business units include Pharmaceutical, Medical Devices and Preventive Medicine Divisions. Pharmaceutical Division is focused on low-dose, orally administered lozenges containing the natural immune system activator interferon-alpha as a treatment for a variety of disease indications. Medical Device Division is developing an insulin pump and further development of point-of-care rapid test kits for the detection and diagnosis of human infections. Preventative Medicine Division is focused on SRNA-based therapeutics.

AIMD Intrinsic Value
0.208 USD
Overvaluation 88%
Intrinsic Value
Price

See Also

What is Ainos Inc's Cash from Operating Activities?
Cash from Operating Activities
-4.6m USD

Based on the financial report for Sep 30, 2025, Ainos Inc's Cash from Operating Activities amounts to -4.6m USD.

What is Ainos Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-28%

Over the last year, the Cash from Operating Activities growth was 27%. The average annual Cash from Operating Activities growth rates for Ainos Inc have been -14% over the past three years , -54% over the past five years , and -28% over the past ten years .

Back to Top